Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency - 03/07/15

Abstract |
Background |
The endonuclease ARTEMIS, which is encoded by the DCLRE1C gene, is a component of the nonhomologous end-joining pathway and participates in hairpin opening during the V(D)J recombination process and repair of a subset of DNA double-strand breaks. Patients with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular radiosensitivity, but hypomorphic mutations can cause milder phenotypes (leaky SCID).
Objective |
We sought to correlate the functional effect of human DCLRE1C mutations on phenotypic presentation in patients with ARTEMIS deficiency.
Methods |
We studied the recombination and DNA repair activity of 41 human DCLRE1C mutations in Dclre1c−/− v-abl kinase–transformed pro-B cells retrovirally engineered with a construct that allows quantification of recombination activity by means of flow cytometry. For assessment of DNA repair efficacy, resolution of γH2AX accumulation was studied after ionizing radiation.
Results |
Low or absent activity was detected for mutations causing a typical SCID phenotype. Most of the patients with leaky SCID were compound heterozygous for 1 loss-of-function and 1 hypomorphic allele, with significant residual levels of recombination and DNA repair activity. Deletions disrupting the C-terminus result in truncated but partially functional proteins and are often associated with leaky SCID. Overexpression of hypomorphic mutants might improve the functional defect.
Conclusions |
Correlation between the nature and location of DCLRE1C mutations, functional activity, and the clinical phenotype has been observed. Hypomorphic variants that have been reported in the general population can be disease causing if combined in trans with a loss-of-function allele. Therapeutic strategies aimed at inducing overexpression of hypomorphic alleles might be beneficial.
Le texte complet de cet article est disponible en PDF.Key words : V(D)J recombination, nonhomologous end-joining, DNA repair, ARTEMIS deficiency, DCLRE1C mutations, severe combined immunodeficiency
Abbreviations used : A-MuLV, ExAC, GFP, IR, LOF, MFI, NHEJ, OS, RAG, RSS, SCID, WT
Plan
| Supported in part by grants P01 AI076210-05 and R01AI00887 from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (to L.D.N.) and March of Dimes grant 1-FY13-500 (to L.D.N.). K.F. received funding from the German Research Foundation (FE 1253/1-1). The JpdeV laboratory is partly funded by Ligue Nationale contre le Cancer (Equipe Labellisée La LIGUE). E.M. is supported by MZCR 00064203 and CZ.2.16/3.1.00/21540. |
|
| Disclosure of potential conflict of interest: K. Felgentreff has received funding from the German Research Foundation (DFG). M. van der Burg's institution has received an Innovational Research Incentives Scheme Vidi (ZonMw) grant (no. 91712323). L. D. Notarangelo is employed by Boston Children's Hospital; has received compensation for board membership from the NIAID and Meyer Children's Hospital, as well as for his role as an Associate Editor at the Journal of Allergy of Clinical Immunology, Journal of Clinical Immunology, and Clinical Immunology; has received grants from the March of Dimes (grant no. 1-FY13-500); and receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 136 - N° 1
P. 140 - juillet 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
